Importance Little guidance exists to date on how to select antipsychotic medications for
patients with first-episode schizophrenia. Objective To develop a preliminary individualized …

Clinical trial efficiency, defined as facilitating patient enrollment, and reducing the time to
reach safety and efficacy decision points, is a critical driving factor for making improvements …

Background At present, no tools exist to estimate objectively the risk of poor treatment
outcomes in patients with first-episode psychosis. Such tools could improve treatment by …

The reproducibility of machine-learning analyses in computational psychiatry is a growing
concern. In a multimodal neuropsychiatric dataset of antipsychotic-naïve, first-episode …

Schizophrenia and related disorders have heterogeneous outcomes. Individualized
prediction of long-term outcomes may be helpful in improving treatment decisions. Utilizing …

Despite advances in sequencing candidate genes and whole genomes, no method has
accurately predicted who will or will not benefit from a specific antipsychotic medication …

Cao et al.[1] reported a clinical tool able to predict response to risperidone treatment in first-
episode drug-naive schizophrenia patients with a balanced accuracy of 82.5%. This work …

Background Choosing the appropriate antipsychotic drug (APD) treatment for patients with
schizophrenia (SCZ) can be challenging, as the treatment response to APD is highly …

Results: In trial 1, 74.5% of individuals responded, with rates significantly higher for
olanzapine (82.1%, 115/140) versus risperidone (66.3%, 69/104; P=. 005). With trial 2 …

Introduction: Affecting~ 1% of the world population, schizophrenia is known as one of the
costliest and most burdensome diseases worldwide. Antipsychotic medications are the main …